Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients

NCT04692181 is registered in ClinicalTrials.gov with Theriva Biologics, Inc. as lead sponsor.

NCT NCT04692181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04692181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients
Lead sponsor
Theriva Biologics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 15, 2021
Completion date
September 30, 2030
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host reaction following bone marrow transplant, prevention of cdi in adult patients being treated with iv beta-lactam antibiotics